durvalumab,Tremelimumab
AstraZeneca
$azn astrazeneca shares data at easl and esmo world gi for imfinzi (durvalumab) combinations in patients with liver and biliary tract cancers 45 seconds delayed.
Democratizing insights.

Not investment advice.